Adjuvant treatment of HER2-positive breast cancer
View Patent ↗Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.
1. A method of increasing invasive disease free survival (IDFS) at 3 years in HER2-positive early breast cancer patients without increase in cardiac toxicity, wherein the patients have a high risk of cancer recurrence, have a baseline left ventricular ejection fraction (LVEF) ≥55%, and have not received prior anti-HER2 therapy, comprising administering to said patients, following surgery, pertuzumab, trastuzumab, and non-anthracycline containing chemotherapy, wherein the non-anthracycline containing chemotherapy comprises 6 cycles every 3 weeks of 75 mg/m 2 docetaxel and 6 times Area Under the Concentration Time Curve (AUC6) carboplatin, wherein pertuzumab and trastuzumab are each administered intravenously starting on day-1 of the first non-anthracycline containing chemotherapy cycle and administered for a total of 52 weeks, and wherein an initial dose of pertuzumab is 840 mg followed every 3 weeks by 420 mg pertuzumab, and an initial dose of trastuzumab is 8 mg/kg followed every 3 weeks by 6 mg/kg trastuzumab, wherein said IDFS at 3 years from initial administration in said patients is increased compared to patients to whom the non-anthracycline containing chemotherapy and trastuzumab without pertuzumab are administered, wherein the cardiac toxicity is a LVEF decline ≥10 points from baseline and a drop to less than 50%, and wherein said high risk patients are node positive or hormone receptor negative.
2. The method of claim 1 , wherein said high risk patients are node positive.
3. The method of claim 1 , wherein said high risk patients are hormone receptor negative.
4. The method of claim 1 , wherein said high risk patients are node positive and hormone receptor negative.
5. A method of increasing invasive disease free survival (IDFS) at 3 years in patients with HER2-positive early breast cancer without increase in cardiac toxicity, comprising administering to said patients, following surgery, pertuzumab, trastuzumab, and taxane-based chemotherapy, wherein the taxane-based chemotherapy comprises 6 cycles every 3 weeks of 75 mg/m 2 docetaxel and 6 times Area Under the Concentration Time Curve (AUC6) carboplatin, wherein pertuzumab and trastuzumab are each intravenously administered starting on Day 1 of the taxane-based chemotherapy cycle and administered for a total of 52 weeks, wherein an initial dose of pertuzumab is 840 mg followed every 3 weeks by 420 mg pertuzumab and an initial dose of trastuzumab is 8 mg/kg followed every 3 weeks by 6 mg/kg trastuzumab, and wherein said IDFS at 3 years from initial administration in said patients is increased compared to patients to whom the taxane-based chemotherapy and trastuzumab without pertuzumab are administered,
wherein the breast cancer is node positive or hormone receptor negative, and
wherein the patients have not received prior anti-HER2 therapy and have a baseline left ventricular ejection fraction (LVEF)≥55%.
6. The method of claim 5 , wherein said patients are node positive.
7. The method of claim 5 , wherein said patients are hormone receptor negative.
8. The method of claim 5 , wherein said patients are node positive and hormone receptor negative.
9. The method of claim 6 , wherein said node positive patients have 4 or more involved lymph nodes.
10. The method of claim 9 , wherein said node positive patients have 4 to 9 involved lymph nodes.
11. The method of claim 5 , wherein said patients have a tumor >2 cm.
12. The method of claim 5 , wherein said cardiac toxicity comprises LVEF decline ≥10 points and a drop to less than 50%.
13. The method of claim 12 , wherein said cardiac toxicity comprises asymptomatic or mildly symptomatic decline in LVEF as defined by NYHA as Class II.
14. The method of claim 12 , wherein said cardiac toxicity further comprises symptomatic heart failure as defined by NYHA as Class III/IV.
15. The method of claim 5 , wherein the maximum dose of carboplatin is 900 mg.